Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

Status unconfirmed · Phase 4

Conditions studied: Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion

In brief

Comparison among three different antithrombotic strategies after percutaneous LAA occlusion with a Watchman FLX LAAC device.

Key facts

Study ID

NCT04502017

Run by

Texas Cardiac Arrhythmia Research Foundation

People needed

360

Starts

2020-08-05

Expected to finish

2023-12-31

Last updated by the study team

2020-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women ≥18 years of age
• Successful LAAC procedure (device implanted without procedural or bleeding complication).
• Patients contraindicated or unsuitable for long-term OAC.
• History of AF (permanent or persistent or paroxysmal).
• Written informed consent by the patient or designee if the patient is unable to consent

You may not qualify if…

• Life expectancy < 2 years.
• Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

Where it is running

• St. David's Medical Center — Austin, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.